Experimental design on single-time-point high-throughput microsomal stability assay

被引:66
作者
Di, L
Kerns, EH
Gao, N
Li, SQ
Huang, YP
Bourassa, JL
Huryn, DM
机构
[1] Wyeth Ayerst Res, Princeton, NJ 08543 USA
[2] Wyeth Ayerst Res, Cambridge, MA 02140 USA
关键词
metabolism; stability; high throughput; absorption; distribution; excretion (ADME); kinetics; liquid chromatography-mass spectrometry-mass; spectrometry (LC-MS-MS);
D O I
10.1002/jps.20076
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
An experimental design for a single-time-point microsomal stability assay was evaluated as compared with multiple-time-point studies. Results obtained from single-time-point experiments are in excellent agreement with those from multiple time points. First-order reaction kinetics revealed rapid changes of predicted half-life from percent remaining of the parent compound at the inflection points, suggesting a maximum predictive limit for half-life. Selection of the incubation time in single-time-point assays is important to obtain balanced information for stable and unstable compounds. A short incubation time (e.g., 5 min) is most useful for differentiating between unstable compounds, which is beneficial to direct the synthetic efforts in projects with poor metabolic stability. A long incubation time (e.g., 30 min) is more applicable to a compound series with high metabolic stability. For screening purposes, a moderate incubation time (e.g., 15 min) is recommended to achieve good resolution and a sufficiently high maximum predictive limit for half-life. This study suggests that a single-time-point assay is sufficient for ranking compounds in early drug discovery. It increases throughput and reduces turnaround time and cost. (C) 2004 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:1537 / 1544
页数:8
相关论文
共 18 条
[1]  
Caldwell GW, 1999, COMB CHEM HIGH T SCR, V2, P39
[2]   In vitro assessment of human cytochrome P450 [J].
Clarke, SE .
XENOBIOTICA, 1998, 28 (12) :1167-1202
[3]   Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates [J].
Di, L ;
Kerns, EH ;
Hong, Y ;
Kleintop, TA ;
McConnell, OJ ;
Huryn, DM .
JOURNAL OF BIOMOLECULAR SCREENING, 2003, 8 (04) :453-462
[4]   Profiling drug-like properties in discovery research [J].
Di, L ;
Kerns, EH .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2003, 7 (03) :402-408
[5]   Advances in in vitro drug metabolism screening [J].
Eddershaw, PJ ;
Dickins, M .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (01) :13-19
[6]   Pharmaceutical profiling in drug discovery [J].
Kerns, EH ;
Di, L .
DRUG DISCOVERY TODAY, 2003, 8 (07) :316-323
[7]   Integrated high capacity solid phase extraction-MS/MS system for pharmaceutical profiling in drug discovery [J].
Kerns, EH ;
Kleintop, T ;
Little, D ;
Tobien, T ;
Mallis, L ;
Di, L ;
Hu, M ;
Hong, Y ;
McConnell, OJ .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 34 (01) :1-9
[8]   High throughput physicochemical profiling for drug discovery [J].
Kerns, EH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (11) :1838-1858
[9]  
Korfmacher WA, 1999, RAPID COMMUN MASS SP, V13, P901, DOI 10.1002/(SICI)1097-0231(19990530)13:10<901::AID-RCM583>3.3.CO
[10]  
2-X